Small molecule inhibitors of fibrosis
AssigneesThe California Institute for Biomedical Research, The Scripps Research Institute
InventorsLuke LAIRSON, Arnab K. CHATTERJEE, Michael BOLLONG, Baiyuan YANG, Peter G. SCHULTZ
Life of this patent
Estimating the term…
Abstract
Described herein are compounds and compositions for the treatment of a fibrotic disease.
Claims180
A compound of Formula (I) having the structure:
- wherein:
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- and
- n is selected from 0, 1, 2, 3, and 4;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (Ia) having the structure:
- wherein:
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), -alkylene(heterocycloalkyl), or
- R2 is alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- and
- n is selected from 0, 1, 2, 3, and 4;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (II) having the structure:
- wherein:
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R4 is halogen, alkyl,
- each R7 is independently selected from halogen and alkyl;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- n is selected from 0, 1, 2, 3, and 4;
- and
- m is selected from 0, 1, and 2;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (IIa) having the structure:
- wherein:
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R4 is halogen, alkyl,
- each R7 is independently selected from halogen and alkyl;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- n is selected from 0, 1, 2, 3, and 4;
- and
- m is selected from 0, 1, and 2;
- or a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, deuteride, N-oxide, stereoisomer, or isomer thereof.
A compound of Formula (III) having the structure:
- wherein:
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- each R5 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
- each R6 is independently selected from halogen, alkyl, and haloalkyl;
- each R7 is independently selected from halogen, alkyl, haloalkyl, and —CN;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- n is selected from 0, 1, 2, 3, and 4;
- p is selected from 0, 1, 2, 3, and 4;
- q is selected from 0, 1, 2, 3, and 4;
- and
- t is selected from 0, 1, 2, 3, and 4;
- wherein at least one p, q, or t is not 0;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (IIIa) having the structure:
- wherein:
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- each R5 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
- each R6 is independently selected from halogen, alkyl, and haloalkyl;
- each R7 is independently selected from halogen, alkyl, haloalkyl, and —CN;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- n is selected from 0, 1, 2, 3, and 4;
- p is selected from 0, 1, 2, 3, and 4;
- q is selected from 0, 1, 2, 3, and 4;
- and
- t is selected from 0, 1, 2, 3, and 4;
- wherein at least one p, q, or t is not 0;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (IV) having the structure:
- wherein:
- R1 is
- —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R4 is halogen, alkyl,
- R5 and R6 are independently selected from H, alkyl, halo, and haloalkyl;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- R20 and R22 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14, wherein at least one of R20 and R22 is not F or Cl;
- each R21 is independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- and
- R23 is H;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (IVa) having the structure:
- wherein:
- R1 is
- —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R4 is halogen, alkyl,
- R5 and R6 are independently selected from H, alkyl, halo, and haloalkyl;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- R20 and R22 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14, wherein at least one of R20 and R22 is not F or Cl;
- each R21 is independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- and
- R23 is H;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (IVb) having the structure:
- wherein:
- R1 is
- —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R4 is halogen, alkyl,
- R5 and R6 are independently selected from H, alkyl, halo, and haloalkyl;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- R20 and R22 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14, wherein at least one of R20 and R22 is not F or Cl;
- each R21 is independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- and
- R23 is H;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (V) having the structure:
- wherein:
- R1 is
- —CH(CH3)CH(R3)CH3, —CH(CH3)C(O)CH3, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R10 is H or alkyl;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- R20 is selected from H, Cl, Br, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- R21, R22, and R23 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- and
- R24 is H;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (Va) having the structure:
- wherein:
- R1 is
- —CH(CH3)CH(R3)CH3, —CH(CH3)C(O)CH3, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R10 is H or alkyl;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- R20 is selected from H, Cl, Br, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- R21, R22, and R23 are independently selected from H, halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- and
- R24 is H;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (VI) having the structure:
- wherein:
- R is
- R2 is H;
- R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- and
- n is selected from 0, 1, 2, 3, and 4;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (VIa) having the structure:
- wherein:
- R1 is
- R2 is H;
- R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- and
- n is selected from 0, 1, 2, 3, and 4;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (VIb) having the structure:
- wherein:
- R1 is
- R2 is H;
- R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- and
- n is selected from 0, 1, 2, 3, and 4;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (VIc) having the structure:
- wherein:
- R1 is
- R2 is H;
- R5 is H, —CN, halogen, haloalkyl, alkyl, —NR13R14, -alkylene(NR13R14), and —SO2R13;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- and
- n is selected from 0, 1, 2, 3, and 4;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound having the structure:
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or pharmaceutically acceptable prodrug thereof.
A compound of Formula (IX) having the structure:
- wherein:
- —X—Y— is —CH2CH2—, —CH═CH—, —CH═N—, or —N═CH—;
- Z1 is selected from O, S, NH, and NR13;
- Z2 is selected from O, S, CH2, NH, and NR13;
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R4 is halogen, alkyl,
- each R7 is independently selected from halogen and alkyl;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- each R15 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
- each R16 is independently selected from halogen, alkyl, and haloalkyl;
- each R17 is independently selected from halogen, alkyl, haloalkyl, and —CN;
- n is selected from 0, 1, 2, 3, and 4;
- m is selected from 0, 1, and 2;
- p is selected from 0, 1, 2, 3, and 4;
- q is selected from 0, 1, 2, 3, and 4;
- and
- t is independently selected from 0, 1, 2, 3, and 4;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable prodrug, or stereoisomer thereof.
A compound of Formula (IXa) having the structure:
- wherein:
- —X—Y— is —CH2CH2—, —CH═CH—, —CH═N—, or —N═CH—;
- Z1 is selected from O, S, NH, and NR13;
- Z2 is selected from O, S, CH2, NH, and NR13;
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- R4 is halogen, alkyl,
- each R7 is independently selected from halogen and alkyl;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- each R15 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
- each R16 is independently selected from halogen, alkyl, and haloalkyl;
- each R17 is independently selected from halogen, alkyl, haloalkyl, and —CN;
- n is selected from 0, 1, 2, 3, and 4;
- m is selected from 0, 1, and 2;
- p is selected from 0, 1, 2, 3, and 4;
- q is selected from 0, 1, 2, 3, and 4;
- and
- t is independently selected from 0, 1, 2, 3, and 4;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable prodrug, or stereoisomer thereof.
A compound of Formula (X) having the structure:
- wherein:
- —X—Y— is —CH2CH2—, —CH═CH—, —CH═N—, or —N═CH—;
- Z1 is selected from O, S, NH, and NR13;
- Z2 is selected from O, S, CH2, NH, and NR13;
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- each R15 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
- each R16 is independently selected from halogen, alkyl, and haloalkyl;
- each R17 is independently selected from halogen, alkyl, haloalkyl, and —CN;
- n is selected from 0, 1, 2, 3, and 4;
- p is selected from 0, 1, 2, 3, and 4;
- q is selected from 0, 1, 2, 3, and 4;
- and
- t is independently selected from 0, 1, 2, 3, and 4;
- wherein when Z1 and Z2 are both O then —X—Y— is —CH═CH—, —CH═N—, or —N═CH—;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable prodrug, or stereoisomer thereof.
A compound of Formula (Xa) having the structure:
- wherein:
- —X—Y— is —CH2CH2—, —CH═CH—, —CH═N—, or —N═CH—;
- Z1 is selected from O, S, NH, and NR13;
- Z2 is selected from O, S, CH2, NH, and NR13;
- R1 is —CH(CH3)CH2CH2R2, —CH(CH2CH3)2, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH2CH3)CH(R3)CH3, -alkylene(cycloalkyl), or
- R2 is H, alkyl, or —NR13R14;
- R3 is —OH, alkyl, or —NR13R14;
- each R8 is independently selected from halogen, —OH, —NO2, —N3, —CN, alkyl, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), cycloalkyl, heterocyclyl, aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and each R14 is each independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- each R15 is independently selected from haloalkyl, -alkylene(NR13R14), —NR13R14, and —SO2R13;
- each R16 is independently selected from halogen, alkyl, and haloalkyl;
- each R17 is independently selected from halogen, alkyl, haloalkyl, and —CN;
- n is selected from 0, 1, 2, 3, and 4;
- p is selected from 0, 1, 2, 3, and 4;
- q is selected from 0, 1, 2, 3, and 4;
- and
- t is independently selected from 0, 1, 2, 3, and 4;
- wherein when Z1 and Z2 are both O then —X—Y— is —CH═CH—, —CH═N—, or —N═CH—;
- or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable prodrug, or stereoisomer thereof.
A method to treat fibrosis, a disorder characterized by fibrosis, or a disease characterized by fibrosis, the method comprising administering a composition comprising a therapeutically effective amount of a compound of Formula (XI), a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof:
- wherein:
- A1 and A2 are independently selected from aryl or heteroaryl;
- B is
- C is optionally substituted 5- or 6-membered heterocyclyl or optionally substituted 5- or 6-membered heteroaryl, wherein the heterocyclyl or the heteroaryl contains 1 to 4 nitrogen atoms;
- D is aryl or heteroaryl;
- E is aryl, heteroaryl, carbocyclyl, hetercyclyl, or alkyl;
- each R1, R2, R3, and R4 is independently selected from H, alkyl, haloalkyl, or alkoxy;
- X1 and X2 are independently selected from N and CR5;
- R5 is H, OH, alkyl, or alkoxy;
- each R6 is independently alkyl, haloalkyl, halo, alkoxy, -alkylene(NR13R14), or aryl;
- each R8 is independently selected from alkyl, cycloalkyl, heterocyclyl, halo, hydroxy, nitrile, azido, nitro, alkoxy, haloalkoxy, haloalkyl, hydroxyalkyl, alkoxyalkyl, -alkylene(NR13R14), -alkylene(cycloalkyl), -alkylene(heterocyclyl), aryl, heteroaryl, —SR13, —SOR13, —SO2R13, —SO2NR13R14, —NR13R14, —NR13SO2R14, —NR13C(O)R14, —NR13C(O)OR14, —NR13C(O)NR13R14, —C(O)R14, —C(O)OR14, and —C(O)NR13R14;
- or two adjacent R8 form a heterocyclyl ring;
- each R13 and R14 is independently selected from H, alkyl, cycloalkyl, heterocyclylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl;
- or R13 and R14 taken together form a heterocycle with the atoms to which they are attached;
- Y1 is selected from O, NH, and NR13;
- Y2 is selected from O, CH2, NH, and NR13;
- n is 1, 2, or 3;
- m is 1 or 2;
- p is 1, 2, 3, or 4;
- q is 1, 2, or 3;
- r is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
- s is 0, 1, 2, 3, or 4;
- t is 0, 1, 2, 3, or 4;
- u is 0, 1, 2, 3, 4 or 5;
- and
- v is 0, 1, 2, 3, or 4.
Dependencies are inferred from the claim text.